I Derm Pharma is developing a first-in-class oral therapy for moderate-to-severe psoriasis, utilizing a novel small molecule with a unique, skin-targeted anti-inflammatory mechanism. Unlike biologics or current oral treatments, our candidate offers a convenient, cost-effective solution with a safer profile and strong efficacy, addressing the unmet need for new, safe, and highly effective oral options in the psoriasis market.